A phase III clinical trial of furmonertinib versus gefitinib (FURLONG, NCT03787992) in patients with locally advanced or metastatic EGFR mutation-positive NSCLC showed superior efficacy of furmonertinib compared with gefitinib as first-line therapy in the Chinese population: PFS was 20.8 months in the furmonertinib group vs. 11.1 months in the gefitinib group, along with an acceptable toxicity profile [177]. Here, EGFR is linked to non-small cell lung carcinoma.